Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Double-Blind Method"" wg kryterium: Temat


Tytuł :
A Case for Double-Blind Review.
Autorzy :
Hirshfield LE; Associate professor, Medical Education and Sociology, University of Illinois at Chicago College of Medicine, Chicago, Illinois; ; ORCID: http://orcid.org/0000-0003-0894-2994.
Pokaż więcej
Źródło :
Academic medicine : journal of the Association of American Medical Colleges [Acad Med] 2020 Nov; Vol. 95 (11), pp. 1628.
Typ publikacji :
Letter
MeSH Terms :
Double-Blind Method*
Editorial Policies*
Education, Medical*
Peer Review, Research*
Bias ; Humans
Opinia redakcyjna
Tytuł :
Who knew? The misleading specificity of "double-blind" and what to do about it.
Autorzy :
Lang TA; West China Hospital/Sichuan Medical School Publishing Group, Kirkland, WA, USA. .
Stroup DF; Data for Solutions, Inc., Decatur, GA, USA.
Pokaż więcej
Źródło :
Trials [Trials] 2020 Aug 05; Vol. 21 (1), pp. 697. Date of Electronic Publication: 2020 Aug 05.
Typ publikacji :
Letter
MeSH Terms :
Double-Blind Method*
Randomized Controlled Trials as Topic*
Terminology as Topic*
Research Design/*standards
Humans ; Language
Opinia redakcyjna
Tytuł :
Efficacy and safety of Suxiao Jiuxin Pill in the treatment of stable angina (Qi stagnation and blood stasis syndrome): study protocol of a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Autorzy :
Ruan X; Cardiovascular Department, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.; Cardiovascular Research Institute of Traditional Chinese Medicine, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Li Y; Cardiovascular Department, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.; Cardiovascular Research Institute of Traditional Chinese Medicine, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Sun Y; Institute of Liver Disease, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Jia M; Cardiovascular Department, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Xu X; Cardiovascular Department, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.; Cardiovascular Research Institute of Traditional Chinese Medicine, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Huo L; Cardiovascular Department, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Song W; Cardiovascular Department, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Yao Y; Cardiovascular Department, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Wang X; Cardiovascular Department, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China. .; Cardiovascular Research Institute of Traditional Chinese Medicine, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. .
Pokaż więcej
Źródło :
Trials [Trials] 2021 Jul 19; Vol. 22 (1), pp. 466. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji :
Clinical Trial Protocol; Journal Article
MeSH Terms :
Angina, Stable*/diagnosis
Angina, Stable*/drug therapy
Drugs, Chinese Herbal*/adverse effects
China ; Double-Blind Method ; Humans ; Multicenter Studies as Topic ; Prospective Studies ; Qi ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.
Autorzy :
Jensterle M; Department of Endocrinology, Diabetes and Metabolic Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, Zaloška cesta 7, SI-1000, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000, Ljubljana, Slovenia.
Ferjan S; Department of Endocrinology, Diabetes and Metabolic Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, Zaloška cesta 7, SI-1000, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000, Ljubljana, Slovenia.
Battelino T; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000, Ljubljana, Slovenia.; Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, University Medical Centre Ljubljana, Bohoričeva 20, SI-1000, Ljubljana, Slovenia.
Kovač J; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000, Ljubljana, Slovenia.; Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, University Medical Centre Ljubljana, Bohoričeva 20, SI-1000, Ljubljana, Slovenia.
Battelino S; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000, Ljubljana, Slovenia.; Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Zaloška cesta 2, SI-1000, Ljubljana, Slovenia.
Šuput D; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000, Ljubljana, Slovenia.
Vovk A; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000, Ljubljana, Slovenia.
Janež A; Department of Endocrinology, Diabetes and Metabolic Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, Zaloška cesta 7, SI-1000, Ljubljana, Slovenia. .; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000, Ljubljana, Slovenia. .
Pokaż więcej
Źródło :
Trials [Trials] 2021 Jul 19; Vol. 22 (1), pp. 464. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji :
Clinical Trial Protocol; Journal Article
MeSH Terms :
Diabetes Mellitus, Type 2*
Glucagon-Like Peptide-1 Receptor*
Double-Blind Method ; Female ; Glucagon-Like Peptides ; Humans ; Hypoglycemic Agents/adverse effects ; Obesity/diagnosis ; Obesity/drug therapy ; Perception ; Randomized Controlled Trials as Topic ; Single-Blind Method ; Taste
Czasopismo naukowe
Tytuł :
The effect of vitamin D supplementation on circulating osteoprogenitor cells: A pilot randomized controlled trial.
Autorzy :
Feehan J; Department of Medicine - Western Health, The University of Melbourne, Melbourne, Victoria, Australia; Osteosarcopenia and Geroscience Research Program, Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne, Western Health, Melbourne, Victoria, Australia.
Degabrielle E; Department of Medicine - Western Health, The University of Melbourne, Melbourne, Victoria, Australia.
Tripodi N; Osteosarcopenia and Geroscience Research Program, Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne, Western Health, Melbourne, Victoria, Australia; Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia.
Al Saedi A; Department of Medicine - Western Health, The University of Melbourne, Melbourne, Victoria, Australia; Osteosarcopenia and Geroscience Research Program, Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne, Western Health, Melbourne, Victoria, Australia.
Vogrin S; Department of Medicine - Western Health, The University of Melbourne, Melbourne, Victoria, Australia; Osteosarcopenia and Geroscience Research Program, Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne, Western Health, Melbourne, Victoria, Australia.
Duque G; Department of Medicine - Western Health, The University of Melbourne, Melbourne, Victoria, Australia; Osteosarcopenia and Geroscience Research Program, Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne, Western Health, Melbourne, Victoria, Australia; Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia. Electronic address: .
Pokaż więcej
Źródło :
Experimental gerontology [Exp Gerontol] 2021 Jul 15; Vol. 150, pp. 111399. Date of Electronic Publication: 2021 May 07.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Vitamin D Deficiency*
Aged ; Cholecalciferol ; Dietary Supplements ; Double-Blind Method ; Humans ; Pilot Projects ; Vitamin D ; Vitamins
Czasopismo naukowe
Tytuł :
JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study.
Autorzy :
Zhang J; Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Che H; Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zhang B; Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zhang C; Department of Gastroenterology, Oriental Hospital, Beijing University of Chinese Medicine, Beijing, China.
Zhou B; Department of Gastroenterology, Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine, Beijing, China.
Ji H; Shanxi Province Academy of Traditional Chinese Medicine, Taiyuan, China.
Xie J; Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Shi X; Institute of Acupuncture and Moxibustion, Chinese Academy of traditional Chinese Medicine, Beijing, China.
Li X; Beijing University of Chinese Medicine, Beijing, China.
Wang F; Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: .
Tang X; China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: .
Pokaż więcej
Źródło :
Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2021 Jul 15; Vol. 88, pp. 153584. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Drugs, Chinese Herbal/*therapeutic use
Gastroesophageal Reflux/*drug therapy
Omeprazole/*administration & dosage
Proton Pump Inhibitors/*administration & dosage
Adult ; Complementary Therapies ; Double-Blind Method ; Female ; Gastroesophageal Reflux/etiology ; Gastrointestinal Agents/therapeutic use ; Humans ; Male ; Middle Aged ; Omeprazole/therapeutic use ; Proton Pump Inhibitors/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Autorzy :
Ashina M; Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600 Glostrup, Copenhagen, Denmark. .
Cohen JM; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Galic M; Teva Pharmaceuticals, Amsterdam, The Netherlands.
Campos VR; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Barash S; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Ning X; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Kessler Y; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Janka L; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Diener HC; Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty of the University Duisburg-Essen, Essen, Germany.
Pokaż więcej
Źródło :
The journal of headache and pain [J Headache Pain] 2021 Jul 10; Vol. 22 (1), pp. 68. Date of Electronic Publication: 2021 Jul 10.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal*
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Calcitonin Gene-Related Peptide ; Double-Blind Method ; Humans ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation.
Autorzy :
Panda SK; Olene Life Sciences Private Limited, Chennai, Tamil Nadu, India.
Nirvanashetty S; Olene Life Sciences Private Limited, Chennai, Tamil Nadu, India.
Missamma M; Clinical Research, Vimta Labs Ltd, Hyderabad, Telangana, India.
Jackson-Michel S; Dolcas Biotech LLC, Landing, NJ.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Jul 09; Vol. 100 (27), pp. e26601.
Typ publikacji :
Journal Article
MeSH Terms :
Curcumin/*analogs & derivatives
Curcumin/*pharmacokinetics
Plant Extracts/*pharmacokinetics
Adolescent ; Adult ; Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics ; Biological Availability ; Cross-Over Studies ; Double-Blind Method ; Humans ; Male ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł :
The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit/hyperactivity disorder: A non-randomized prospective interventional study.
Autorzy :
Sugimoto A; Department of Community Psychiatric Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.; Department of Psychiatry, Niigata Psychiatric Center, Nagaoka, Japan.
Suzuki Y; Department of Psychiatry, Niigata University Medical and Dental Hospital, Niigata, Japan.; Department of Psychiatry, Suehirobashi Hospital Keiaikai, Niigata, Japan.
Orime N; Department of Psychiatry, Niigata University Medical and Dental Hospital, Niigata, Japan.
Hayashi T; Department of Psychiatry, Niigata Psychiatric Center, Nagaoka, Japan.
Yoshinaga K; Department of Psychiatry, Niigata Psychiatric Center, Nagaoka, Japan.; Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Egawa J; Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Ono S; Department of Community Psychiatric Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.; Department of Psychiatry, Niigata Psychiatric Center, Nagaoka, Japan.
Sugai T; Comprehensive Medical Education Center, Niigata University School of Medicine, Niigata, Japan.
Inoue Y; Department of Psychiatry, Dokkyo Medical University, Soka, Japan.
Someya T; Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Jul 09; Vol. 100 (27), pp. e26552.
Typ publikacji :
Clinical Study; Journal Article
MeSH Terms :
Atomoxetine Hydrochloride/*pharmacokinetics
Attention Deficit Disorder with Hyperactivity/*drug therapy
Adrenergic Uptake Inhibitors/pharmacokinetics ; Attention Deficit Disorder with Hyperactivity/blood ; Child ; Double-Blind Method ; Female ; Humans ; Male ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The use of an alternating magnetic field in the resorption of postoperative joint effusion following anterior cruciate ligament reconstruction: A randomized double-blind controlled trial.
Autorzy :
Ogrodzka-Ciechanowicz K; Institute of Clinical Rehabilitation, Faculty of Motor Rehabilitation, University of Physical Education in Krakow, Poland.
Głąb G; Institute of Clinical Rehabilitation, Faculty of Motor Rehabilitation, University of Physical Education in Krakow, Poland.
Ciszek-Radwan E; Institute of Clinical Rehabilitation, Faculty of Motor Rehabilitation, University of Physical Education in Krakow, Poland.
Ślusarski J; Trauma and Orthopaedics Clinical Department, University Hospital in Krakow, Poland.
Gądek A; Trauma and Orthopaedics Clinical Department, University Hospital in Krakow, Poland.; Department of Orthopedics and Physiotherapy, Jagiellonian University Collegium Medicum, Poland.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Jul 09; Vol. 100 (27), pp. e26572.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Magnetic Fields*
Anterior Cruciate Ligament Injuries/*surgery
Anterior Cruciate Ligament Reconstruction/*adverse effects
Knee Joint/*surgery
Postoperative Complications/*therapy
Range of Motion, Articular/*physiology
Recovery of Function/*physiology
Adolescent ; Adult ; Double-Blind Method ; Female ; Humans ; Knee Joint/physiopathology ; Male ; Postoperative Complications/etiology ; Postoperative Complications/physiopathology ; Young Adult
Czasopismo naukowe
Tytuł :
Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival: study protocol of a multicenter, randomized, single-blind, placebo-controlled trial.
Autorzy :
Chen Y; Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Back Road of Art Gallery, Dongcheng District, Beijing, 100010, China.
Yu M; Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Back Road of Art Gallery, Dongcheng District, Beijing, 100010, China.
Liu Z; Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Back Road of Art Gallery, Dongcheng District, Beijing, 100010, China.
Zhang Y; Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Back Road of Art Gallery, Dongcheng District, Beijing, 100010, China.
Li Q; Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Back Road of Art Gallery, Dongcheng District, Beijing, 100010, China.
Yang G; Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Back Road of Art Gallery, Dongcheng District, Beijing, 100010, China. .
Pokaż więcej
Źródło :
Trials [Trials] 2021 Jul 08; Vol. 22 (1), pp. 437. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji :
Clinical Trial Protocol; Journal Article
MeSH Terms :
Lung Neoplasms*/drug therapy
Medicine, Chinese Traditional*
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Double-Blind Method ; Humans ; Multicenter Studies as Topic ; Prospective Studies ; Quality of Life ; Randomized Controlled Trials as Topic ; Single-Blind Method
Czasopismo naukowe
Tytuł :
Bimekizumab versus Secukinumab in Plaque Psoriasis.
Autorzy :
Reich K; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Warren RB; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Lebwohl M; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Gooderham M; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Strober B; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Langley RG; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Paul C; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
De Cuyper D; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Vanvoorden V; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Madden C; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Cioffi C; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Peterson L; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Blauvelt A; From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Jul 08; Vol. 385 (2), pp. 142-152. Date of Electronic Publication: 2021 Apr 23.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Interleukin-17/*antagonists & inhibitors
Psoriasis/*drug therapy
Adult ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Candidiasis, Oral/etiology ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Injections, Subcutaneous ; Intention to Treat Analysis ; Male ; Middle Aged ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Bimekizumab versus Adalimumab in Plaque Psoriasis.
Autorzy :
Warren RB; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Blauvelt A; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Bagel J; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Papp KA; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Yamauchi P; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Armstrong A; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Langley RG; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Vanvoorden V; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
De Cuyper D; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Cioffi C; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Peterson L; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Cross N; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Reich K; From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Jul 08; Vol. 385 (2), pp. 130-141. Date of Electronic Publication: 2021 Apr 23.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Interleukin-17/*antagonists & inhibitors
Psoriasis/*drug therapy
Adalimumab/administration & dosage ; Adalimumab/adverse effects ; Adult ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Candidiasis, Oral/etiology ; Diarrhea/chemically induced ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
25-OHD response to vitamin D supplementation in children: effect of dose but not GC haplotype.
Autorzy :
Simpson CA; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Zhang JH; Veterans Administration Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, Connecticut, USA.
Vanderschueren D; Department of Chronic Diseases, Metabolism and Ageing, Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Belgium.
Fu L; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.; Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Pennestri TC; Department of Pediatrics (Endocrinology), Yale University School of Medicine, New Haven, Connecticut, USA.
Bouillon R; Department of Chronic Diseases, Metabolism and Ageing, Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Belgium.
Cole DEC; Departments of Laboratory Medicine and Pathobiology, Medicine, and Genetics, University of Toronto, and Sunnybrook Health Center, Toronto, Ontario, Canada.
Carpenter TO; Department of Pediatrics (Endocrinology), Yale University School of Medicine, New Haven, Connecticut, USA.
Pokaż więcej
Źródło :
European journal of endocrinology [Eur J Endocrinol] 2021 Jul 07; Vol. 185 (2), pp. 333-342. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
25-Hydroxyvitamin D 2/*blood
Cholecalciferol/*administration & dosage
Cholecalciferol/*blood
Haplotypes/*physiology
Vitamin D Deficiency/*blood
Vitamin D Deficiency/*diet therapy
Child ; Child, Preschool ; Dietary Supplements ; Double-Blind Method ; Female ; Humans ; Infant ; Male ; Prospective Studies ; Vitamin D Deficiency/diagnosis
Czasopismo naukowe
Tytuł :
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
Autorzy :
Cohen MS; Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill.
Nirula A; Eli Lilly and Co, Indianapolis, Indiana.
Mulligan MJ; New York University Langone Vaccine Center, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, New York.
Novak RM; University of Illinois College of Medicine, Chicago.
Marovich M; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.
Yen C; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.
Stemer A; Indiana University School of Medicine, Gary.
Mayer SM; University of Illinois College of Medicine, Chicago.
Wohl D; Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill.
Brengle B; Brengle Family Medicine, Indianapolis, Indiana.
Montague BT; Division of Infectious Diseases, University of Colorado School of Medicine, Aurora.
Frank I; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia.
McCulloh RJ; University of Nebraska Medical Center, Omaha.
Fichtenbaum CJ; University of Cincinnati Academic Health Center, Cincinnati, Ohio.
Lipson B; Florida Primary and Specialty Care, Boca Raton.
Gabra N; Burke Internal Medicine & Research, Burke, Virginia.
Ramirez JA; Division of Infectious Diseases, University of Louisville School of Medicine, Louisville, Kentucky.
Thai C; private practice, Huntington Beach, California.
Chege W; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.
Gomez Lorenzo MM; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.
Sista N; FHI 360, Durham, North Carolina.
Farrior J; FHI 360, Durham, North Carolina.
Clement ME; Louisiana State University Health Sciences Center, New Orleans.
Brown ER; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Custer KL; Eli Lilly and Co, Indianapolis, Indiana.
Van Naarden J; Eli Lilly and Co, Indianapolis, Indiana.
Adams AC; Eli Lilly and Co, Indianapolis, Indiana.
Schade AE; Eli Lilly and Co, Indianapolis, Indiana.
Dabora MC; Eli Lilly and Co, Indianapolis, Indiana.
Knorr J; Eli Lilly and Co, Indianapolis, Indiana.
Price KL; Eli Lilly and Co, Indianapolis, Indiana.
Sabo J; Eli Lilly and Co, Indianapolis, Indiana.
Tuttle JL; Eli Lilly and Co, Indianapolis, Indiana.
Klekotka P; Eli Lilly and Co, Indianapolis, Indiana.
Shen L; Eli Lilly and Co, Indianapolis, Indiana.
Skovronsky DM; Eli Lilly and Co, Indianapolis, Indiana.
Pokaż więcej
Corporate Authors :
BLAZE-2 Investigators
Źródło :
JAMA [JAMA] 2021 Jul 06; Vol. 326 (1), pp. 46-55.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Antibodies, Neutralizing/*therapeutic use
Antiviral Agents/*therapeutic use
COVID-19/*prevention & control
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/immunology ; Antiviral Agents/adverse effects ; Antiviral Agents/immunology ; Assisted Living Facilities ; COVID-19/epidemiology ; Double-Blind Method ; Drug Approval ; Female ; Health Personnel ; Humans ; Immunization, Passive ; Incidence ; Infusions, Intravenous ; Male ; Middle Aged ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Skilled Nursing Facilities ; Young Adult
SCR Organism :
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł :
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
Autorzy :
Al Kaabi N; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Zhang Y; China National Biotec Group Company Limited, Beijing, China.
Xia S; Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan, China.
Yang Y; China National Biotec Group Company Limited, Beijing, China.
Al Qahtani MM; Bahrain Defence Force Royal Medical Services, Military Hospital, Kingdom of Bahrain.
Abdulrazzaq N; Ministry of Health and Prevention, Abu Dhabi, United Arab Emirates.
Al Nusair M; Prince Hamza Hospital, Amman, Jordan.
Hassany M; Ministry of Health, Cairo, Egypt.
Jawad JS; Ministry of Health, Kingdom of Bahrain.
Abdalla J; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Hussein SE; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Al Mazrouei SK; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Al Karam M; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Li X; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Yang X; China National Biotec Group Company Limited, Beijing, China.
Wang W; Beijing Institute of Biological Products Co, Ltd, Beijing, China.
Lai B; China National Biotec Group Company Limited, Beijing, China.
Chen W; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Huang S; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Wang Q; China National Biotec Group Company Limited, Beijing, China.
Yang T; China National Biotec Group Company Limited, Beijing, China.
Liu Y; China National Biotec Group Company Limited, Beijing, China.
Ma R; Beijing Institute of Biological Products Co, Ltd, Beijing, China.
Hussain ZM; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Khan T; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
Saifuddin Fasihuddin M; Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.
You W; Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan, China.
Xie Z; Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan, China.
Zhao Y; Beijing Institute of Biological Products Co, Ltd, Beijing, China.
Jiang Z; Beijing Key-Tech Statistical Consulting Co, Ltd, Beijing, China.
Zhao G; Beijing Key-Tech Statistical Consulting Co, Ltd, Beijing, China.
Zhang Y; Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Mahmoud S; G42 Healthcare, Abu Dhabi, United Arab Emirates.
ElTantawy I; G42 Healthcare, Abu Dhabi, United Arab Emirates.
Xiao P; G42 Healthcare, Abu Dhabi, United Arab Emirates.
Koshy A; Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zaher WA; G42 Healthcare, Abu Dhabi, United Arab Emirates.
Wang H; Beijing Institute of Biological Products Co, Ltd, Beijing, China.
Duan K; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Pan A; Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yang X; China National Biotec Group Company Limited, Beijing, China.; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China.
Pokaż więcej
Źródło :
JAMA [JAMA] 2021 Jul 06; Vol. 326 (1), pp. 35-45.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Adult ; COVID-19/immunology ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/adverse effects ; Datasets as Topic ; Double-Blind Method ; Female ; Humans ; Injections, Intramuscular ; Male ; Middle Aged ; Middle East ; Vaccines, Inactivated/immunology
Czasopismo naukowe
Tytuł :
Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine:a phase I clinical trial.
Autorzy :
Wu ZW; Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
Li QL; Wuhan Institute of Biological Products Co., Ltd., Wuhan, People's Republic of China.
Zhou HS; Zhengding County Center for Disease Control and Prevention, Zhengding, People's Republic of China.
Duan K; Wuhan Institute of Biological Products Co., Ltd., Wuhan, People's Republic of China.
Gao Z; Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
Zhang XJ; Zhengding County Center for Disease Control and Prevention, Zhengding, People's Republic of China.
Jiang ZJ; Wuhan Institute of Biological Products Co., Ltd., Wuhan, People's Republic of China.
Hao ZY; Zhengding County Center for Disease Control and Prevention, Zhengding, People's Republic of China.
Jin F; Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
Bai X; Wuhan Institute of Biological Products Co., Ltd., Wuhan, People's Republic of China.
Li Q; Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
Xu GL; Wuhan Institute of Biological Products Co., Ltd., Wuhan, People's Republic of China.
Zhao YL; Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
Yang XM; Wuhan Institute of Biological Products Co., Ltd., Wuhan, People's Republic of China.
Pokaż więcej
Źródło :
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Jul 03; Vol. 17 (7), pp. 2311-2318. Date of Electronic Publication: 2021 Feb 05.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Rotavirus*
Rotavirus Infections*/prevention & control
Rotavirus Vaccines*/adverse effects
Adult ; Antibodies, Viral ; China ; Double-Blind Method ; Humans ; Immunogenicity, Vaccine ; Infant ; Vaccines, Attenuated/adverse effects ; Vaccines, Combined
Czasopismo naukowe
Tytuł :
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
Autorzy :
Vallejos J; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
Zoni R; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina. .
Bangher M; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
Villamandos S; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
Bobadilla A; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Plano F; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
Campias C; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Chaparro Campias E; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Medina MF; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
Achinelli F; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
Guglielmone HA; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Ojeda J; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
Farizano Salazar D; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
Andino G; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Kawerin P; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Dellamea S; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
Aquino AC; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
Flores V; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
Martemucci CN; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Martinez SM; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Segovia JE; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Reynoso PI; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
Sosa NC; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
Robledo ME; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
Guarrochena JM
Vernengo MM; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Ruiz Diaz N; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Meza E; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
Aguirre MG; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2021 Jul 02; Vol. 21 (1), pp. 635. Date of Electronic Publication: 2021 Jul 02.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
Ivermectin/*therapeutic use
Adult ; Antiviral Agents/adverse effects ; COVID-19/etiology ; COVID-19/virology ; COVID-19 Nucleic Acid Testing ; Double-Blind Method ; Female ; Hospitalization ; Humans ; Ivermectin/adverse effects ; Length of Stay ; Male ; Middle Aged ; Nasopharynx/virology ; Placebos ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Comparison of efficacy between palonosetron-midazolam combination and palonosetron alone for prevention of postoperative nausea and vomiting in patients undergoing breast surgery and patient controlled analgesia: A prospective, randomized, double-blind study: A CONSORT-compliant study.
Autorzy :
Hong JM; Department of Anesthesia and Pain Medicine.; Biomedical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan-si 49241, Korea.
Han YH; Department of Anesthesia and Pain Medicine.
Lee D; Department of Anesthesia and Pain Medicine.
Hwang BY; Department of Anesthesia and Pain Medicine.
Baik J; Department of Anesthesia and Pain Medicine.
Cho AR; Department of Anesthesia and Pain Medicine.
Lee HJ; Department of Anesthesia and Pain Medicine.
Kim E; Department of Anesthesia and Pain Medicine.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Jul 02; Vol. 100 (26), pp. e26438.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Fentanyl*/administration & dosage
Fentanyl*/adverse effects
Postoperative Nausea and Vomiting*/etiology
Postoperative Nausea and Vomiting*/prevention & control
Analgesia, Patient-Controlled/*adverse effects
Breast Neoplasms/*surgery
Midazolam/*administration & dosage
Palonosetron/*administration & dosage
Anesthetics, Intravenous/administration & dosage ; Antiemetics/administration & dosage ; Antiemetics/adverse effects ; Double-Blind Method ; Drug Therapy, Combination/methods ; Female ; Humans ; Mastectomy/adverse effects ; Mastectomy/methods ; Midazolam/adverse effects ; Middle Aged ; Palonosetron/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Efficacy of GCWB106 (Chrysanthemum zawadskii var. latilobum extract) in osteoarthritis of the knee: A 12-week randomized, double-blind, placebo-controlled study.
Autorzy :
Ha JK; Department of Orthopedic Surgery and Sports Medical Center and Sports Medical Research Institute, Seoul Paik Hospital, College of Medicine, Inje University, Seoul, Republic of Korea.
Kim JS; Department of Orthopedic Surgery and Sports Medical Center and Sports Medical Research Institute, Seoul Paik Hospital, College of Medicine, Inje University, Seoul, Republic of Korea.
Kim JY; GC Wellbeing Corporation, Seoul, Republic of Korea.
Yun JB; GC Wellbeing Corporation, Seoul, Republic of Korea.
Kim YY; Department of Orthopedic Surgery and Sports Medical Center and Sports Medical Research Institute, Seoul Paik Hospital, College of Medicine, Inje University, Seoul, Republic of Korea.
Chung KS; Department of Orthopedic Surgery and Sports Medical Center and Sports Medical Research Institute, Seoul Paik Hospital, College of Medicine, Inje University, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Jul 02; Vol. 100 (26), pp. e26542.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Arthralgia*/diagnosis
Arthralgia*/drug therapy
Arthralgia*/etiology
Chrysanthemum*
Osteoarthritis, Knee*/diagnosis
Osteoarthritis, Knee*/drug therapy
Osteoarthritis, Knee*/physiopathology
Osteoarthritis, Knee*/psychology
Plant Extracts*/administration & dosage
Plant Extracts*/adverse effects
Quality of Life*
Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Double-Blind Method ; Female ; Functional Status ; Humans ; Male ; Middle Aged ; Pain Measurement/methods ; Plant Components, Aerial ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies